Puma Biotech (PBYI) Reports Q2 Loss of $1.13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PBYI Hot Sheet
Join SI Premium – FREE
Puma Biotech (NYSE: PBYI) reported Q2 EPS of ($1.13), versus ($1.05) reported last year.
For earnings history and earnings-related data on Puma Biotech (PBYI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corpay, Inc. (CPAY) Tops Q3 EPS by 35c; offers guidance
- Klaviyo, Inc. (KVYO) Tops Q3 EPS by 26c, Beats on Revenue; Offers FY26 Revenue Guidance
- TKO Group Holdings (TKO) Tops Q3 EPS by 11c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
